---
title: "Relapsed Refractory Disease of Diffuse large B-cell lymphoma"
slug: "relapsed-refractory-disease-of-diffuse-large-b-cell-lymphoma"
date: "2023-06-05"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Diffuse large B-cell lymphoma]]

[[2024-06-22-innovative_therapies_for_relapsed-refractory-disease-of-diffuse-large-b-cell-lymphoma.md|2024-06-22-Innovative Therapies for relapsed-refractory-disease-of-diffuse-large-b-cell-lymphoma]]

# Relapsed Refractory Disease of Diffuse large B-cell lymphoma

[[Video sum of Relapsed Refractory Disease of Diffuse large B-cell lymphoma]]

[[Transplant Eligible of Relapsed Refractory Disease of Diffuse large B-cell lymphoma]]

## Q: åœ¨ â†£ ç¼ºä¹æ²»æ„ˆæ–¹æ¡ˆçš„ â†’ æƒ…å†µä¸‹ï¼Œå¦‚ä½•ç»™äºˆè¯ç‰©æ²»ç–—ä»¥ç¼“è§£ç—…æƒ…ï¼Ÿ

A: æä¾›ä»¥ç¼“è§£ä¸ºç›®çš„ â†’ çš„å¤„æ–¹è¯ç‰©æ²»ç–—ã€‚
ğŸ‘‰ğŸ»: No curative option available; Rx given w/ palliative intent.

## Q: åœ¨ â†£ é€‰æ‹©æ²»ç–—æ–¹æ¡ˆæ—¶ï¼Œä¾æ®å“ªäº›å› ç´ æ¥å†³å®šï¼Ÿ

A: å–å†³äºå…ˆå‰æ²»ç–—å’Œç–—æ•ˆ

- å¯¹äºåœ¨ â†£ è‡³å°‘ä¸¤ä¸ªå‰çº¿ç»†èƒæ¯’åŒ–ç–—è¯ç‰©æ²»ç–—æ— æ•ˆçš„ â†’ æ‚£è€…ï¼Œç»§ç»­ä½¿ç”¨å…¶ä»–è¯ç‰©æ²»ç–—çš„ â†’ ååº”å¯èƒ½å¾ˆå°ã€‚
  ğŸ‘‰ğŸ»: Choice of regimen depends on prior tx & response. Pts refractory to â‰¥2 prior lines of cytotoxic chemotherapy are unlikely to respond to additional lines.

## Q: å¦‚ä½•åˆ©ç”¨å§‘æ¯æ€§æ”¾ç–—æ¥å¸®åŠ©ç¼“è§£ç—‡çŠ¶æ€§ç—…ç¶ï¼Ÿ

A: å§‘æ¯æ€§æ”¾ç–—å¯¹äºç¼“è§£ç—‡çŠ¶æ€§ç—…ç¶å¾ˆæœ‰ç”¨ã€‚
ğŸ‘‰ğŸ»: Palliative RT useful for symptomatic lesions.

## Q: åœ¨ â†£ ä¸´åºŠè¯•éªŒä¸­ï¼Œæœ‰å“ªäº›è¯ç‰©æ­£åœ¨ â†£ ç ”ç©¶ä¸­ï¼Ÿ

A: é¼“åŠ±å‚ä¸ä¸´åºŠè¯•éªŒ

- ç›®å‰æ­£åœ¨ â†£ ç ”ç©¶çš„ â†’ è¯ç‰©åŒ…æ‹¬ â‰¡ ä¼Šå¸ƒæ›¿å°¼ï¼ˆåœ¨ â†£ ABC äºšå‹ä¸­å¯èƒ½è¡¨ç°æ›´å¥½ï¼‰ï¼Œæ¥é‚£åº¦èƒºï¼Œç»´å¥ˆæ›¿å…‹æ‹‰ï¼Œå¸•è¯ºæ¯”å°¼æ–¯å¡”ï¼ŒåµŒåˆæŠ—åŸå—ä½“ï¼ˆCARï¼‰ä¿®é¥°çš„ â†’ T ç»†èƒå’Œæ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ã€‚
  ğŸ‘‰ğŸ»: Encourage clinical trials. Agents under investigation include ibrutinib (may perform better in ABC subtype), lenalidomide, venetoclax, panobinostat, chimeric antigen receptor (CAR) modified T cells, checkpoint inhibitors.
